# EdiGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edigene

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.edigene.com
- Total disclosed funding: $165M
- Latest round: Series B (Apr 21, 2021)
- Investors on record: 12

## About

EdiGene Inc., based in Beijing, China, is a biotechnology company specializing in innovative gene editing and cellular therapy solutions aimed at addressing critical healthcare challenges, including genetic diseases and cancer.Founded in 2015 in Beijing, China, EdiGene Inc. operates in the biotechnology sector, focusing on gene editing and cellular therapies. The company's recent funding round in April 2021 was a Series B, raising RMB 400 million led by Loyal Valley Capital, with participation from various investors.  EdiGene has completed a total of 7 deals to date.EdiGene Inc. specializes in advanced gene editing and cellular therapy solutions, focusing on high-throughput genomic editing, allogeneic cell therapy, and in vivo RNA base editing platforms. Their core product offerings aim to address significant healthcare challenges such as genetic diseases and cancer, providing innovative approaches to treatment. The genomic editing platform enables researchers and healthcare providers to make precise modifications to genes, facilitating potential breakthroughs in therapeutic applications. EdiGene’s clientele includes research institutions, biotechnology companies, and healthcare providers, particularly within the Asia-Pacific region, where they are actively engaged in delivering these pioneering solutions to combat prevalent health issues.EdiGene's revenue model is structured around B2B collaborations and service agreements with research institutions and healthcare organizations. Transactions typically occur through partnerships that involve the provision of gene editing services and cellular therapies tailored to specific client needs. The company’s flagship offerings include proprietary gene editing technologies that are incorporated into client projects, with revenue generated through service fees or project-based contracts. These business interactions focus on long-term partnerships rather than direct consumer sales, ensuring that clients benefit from continuous support and access to advancements in gene therapy. The financial transactions reflect the value of EdiGene’s innovative services, underscoring their role in shaping the future of genetic medicine.EdiGene Inc. is positioned for growth through the development of upcoming products in gene editing and cellular therapies, with a focus on expanding into new markets in the Asia-Pacific region by the end of 2023. The company intends to utilize the RMB 400 million raised in its Series B funding round to support these initiatives, which include enhancing their existing platforms and increasing their capacity to serve a growing client base in genetic medicine.

## Funding rounds

- Series B, Apr 21, 2021, $62M — Hong Shan, IDG Capital, Lilly Asia Ventures, Huagai Capital, Loyal Valley Capital, Alwin Capital, Shanhai Capital, BioTrack Capital, Sherpa Healthcare Partners, 3H Health Investment
- Series B, Oct 13, 2020, $67M — Hong Shan, IDG Capital, Lilly Asia Ventures, Green Pine Capital Partners, Huagai Capital, Alwin Capital, Shanhai Capital, 3H Health Investment
- Series A, Sep 16, 2019, $11M — IDG Capital, Lilly Asia Ventures
- Series A, Feb 4, 2019, $10M — IDG Capital, Lilly Asia Ventures, Green Pine Capital Partners
- Series A, Aug 8, 2018, $15M — WI Harper Group, IDG Capital, Lilly Asia Ventures, Huagai Capital
- Series A, Sep 22, 2016 — WI Harper Group, IDG Capital

## Investors

- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series A
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A, Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A, Series B
- Hong Shan — Series B
- Alwin Capital — Series B
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series B
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B